New hope for hemophilia bleeds: clotting concentrate tested in 30 patients

NCT ID NCT07406139

Recruiting now Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Feb 16, 2026 · Last updated May 07, 2026 · Updated 14 times

Summary

This study tests a clotting medicine called prothrombin complex concentrate (PCC) to stop bleeding in people with hemophilia A who have developed inhibitors (antibodies that block standard treatment). About 30 participants aged 12 to 65 will receive PCC on-demand during bleeding episodes. The goal is to see how well and safely it controls bleeding, not to cure the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Institute of haematology and Blood diseases hospital
RECRUITING

Tianjin, Tianjin Municipality, 300020, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HEMOPHILIA INHIBITORS